If you have been reading about bioavailability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Central obesity: waist ≥94 cm (37 in) men; ≥80 cm (31.5 in) women Dyslipidaemia: TG ≥2.0 mmol/L (177 mg/dL) and/or HDL-C <1.0 mmol/L (38.61 mg/dL) or treated for dyslipidaemia Blood pressure ≥140/90 mmHg or antihypertensive medication Fasting plasma glucose ≥6.1 mmol/L (110 mg/dL)
Mammals regulate their core temperature using input from thermoreceptors in the hypothalamus, brain, spinal cord, internal organs, and great veins. Apart from the internal regulation of temperature, a process called allostasis can come into play that adjusts behaviour to adapt to the challenge of very hot or cold extremes (and to other challenges). These adjustments may include seeking shade and reducing activity, seeking warmer conditions and increasing activity, or huddling. Behavioral thermoregulation takes precedence over physiological thermoregulation since necessary changes can be affected more quickly and physiological thermoregulation is limited in its capacity to respond to extreme temperatures. When the core temperature falls, the blood supply to the skin is reduced by intense vasoconstriction. The blood flow to the limbs (which have a large surface area) is similarly reduced and returned to the trunk via the deep veins which lie alongside the arteries (forming venae comitantes). This acts as a counter-current exchange system that short-circuits the warmth from the arterial blood directly into the venous blood returning into the trunk, causing minimal heat loss from the extremities in cold weather. The subcutaneous limb veins are tightly constricted, not only reducing heat loss from this source but also forcing the venous blood into the counter-current system in the depths of the limbs.
== External links == Clinical trial number NCT04020341 for "A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov Clinical trial number NCT04187144 for "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov
Sources: en.wikipedia.org
On 1 April 1974, Powys was created under the Local Government Act 1972. At first, the former administrative counties of Montgomery, Radnor, and Brecknock were districts within it. On 1 April 1996, the districts were abolished, and Powys was reconstituted as a unitary authority. There was a minor border adjustment in the northeast—specifically, the addition of the communities of Llansilin and Llangedwyn from Glyndŵr district in Clwyd—and with moving the border, so that rather than half of Llanrhaeadr-ym-Mochnant, all is included. The first Lord Lieutenant of Powys was previously the Lord Lieutenant of Montgomeryshire. The Lord Lieutenant of Brecknockshire and Lord Lieutenant of Radnorshire were appointed as lieutenants. The present lord lieutenant is Shân Legge-Bourke of Crickhowell.
=== Death of Charles === Charles had been in poor health for some time. After going shopping on a chilly day in Funchal to buy toys for Carl Ludwig, he was struck by an attack of bronchitis. This rapidly worsened into pneumonia, not helped by the inadequate medical care available. Several of the children and staff were also ill, and Zita (at the time eight months pregnant) helped nurse them all. Charles weakened and died on 1 April, his last words to his wife being "I love you so much." Charles was 34 years old. After his funeral, a witness said of Zita "This woman really is to be admired. She did not, for one second, lose her composure... she greeted the people on all sides and then spoke to those who had helped out with the funeral. They were all under her charm." Zita wore mourning black in Charles's memory throughout 67 years of widowhood.
== Figurative use == The term poison is also used in a figurative sense. The slang sense of alcoholic drink is first attested 1805, American English (e.g., a bartender might ask a customer "what's your poison?" or "Pick your poison"). Figurative use of the term dates from the late 15th century. Figuratively referring to persons as poison dates from 1910. The figurative term poison pen letter became well known in 1913 by a notorious criminal case in Pennsylvania, U.S.; the phrase dates to 1898. Despite the plants of the Toxicodendron family having the names poison ivy and poison oak, the oil urushiol they produce is not a true poison and is actually an allergen, which 15% of people are resistant to.
=== Public utilities === Buildings in Moscow, as in other Russian cities, are warmed by district heating. Before 2004, state unitary enterprises were responsible for producing and supplying heat to clients by operating the heating stations and distribution system of Mosgorteplo, Mosteploenergo, and Teploremontnaladka; these provided service to the heating substations in the northeastern part of the city. Clients were divided among enterprises according to location. A major reform launched in 2004 consolidated companies under MIPC, which became the municipal heat supplier. Its subsidiaries were new joint-stock companies. The city's main source of heating is Mosenergo's power station, which was reformed in 2005, when about ten subsidiaries were detached. One of the newly independent companies was the District Heating Network Company (MTK) (Russian: Московская теплосетевая компания). In 2007, the Government of Moscow bought controlling stakes in this company. "Our city" is a geoinformation portal created in 2011 under Moscow's mayor, Sergei Sobyanin, to initiate constructive dialogue between Moscow residents and the city's executive authorities. This portal is being developed by the State Public Institution "New Management Technologies", together with the Moscow Department of Information Technologies. During its 10 years of operation, more than 1.7 million users have registered for the portal; it has become effective for monitoring urban infrastructure.
Sources: en.wikipedia.org
==== MeSH E05.393.183 – chromosome mapping ==== MeSH E05.393.183.250 – chromosome walking MeSH E05.393.183.620 – physical chromosome mapping MeSH E05.393.183.620.160 – contig mapping MeSH E05.393.183.620.405 – radiation hybrid mapping MeSH E05.393.183.620.650 – restriction mapping
== Labeling of cells == How the labeling of RNA molecules is achieved depends on the model organism. For E.coli (bacteria) the minimum medium M9 can be used and supplemented with the stable isotope labeled variants of the needed salts. This enables labeling with 13C-carbon, 15N-nitrogen, 34S-sulfur and 2H-hydrogen. In S.cerevisiae (yeast) there are currently two possibilities: First, the use of commercially available complete growth medium, which enables labeling with 13C-carbon and/or 15N-nitrogen and second the use of minimal YNB medium which has to be supplemented with several amino acids and glucose which can be added as stable isotope labeled variants in order to achieve 13C-carbon, 15N-nitrogen and 2H-hydrogen labeling of RNA. While labeling in model organisms like E.coli and S.cerevisiae is fairly simple, stable isotope labeling in cell culture is much more challenging as the composition of the growth media is much more complex. Neither the supplementation of stable isotope labeled glucose nor the supplementation of stable isotope labeled variants of simple precursors of nucleoside biosynthesis such as glutamine and/or aspartate is sufficient for a defined mass increase higher than 2 Da. Instead, most cells kept in cell culture can be fed with stable isotope labeled methionine for labeling of methyl groups and with stable isotope labeled variants of adenin and uridine for labeling of the nucleoside's base body.
The Lakshman Kadirgamar Institute of International Relations and Strategic Studies is a policy-studies institute that is often referred to as a think tank. LIRNEasia is a think tank working across the Asia-Pacific on regulatory and policy issues. Their main focus is the ICT sector, although they do work in other sectors, such as agriculture and health, which can benefit from ICT. Verité Research is an interdisciplinary think tank in Colombo.
On October 21, 2025, Gallrein announced his candidacy for the United States House of Representatives for Kentucky's 4th congressional district, challenging seven-term incumbent Thomas Massie in the Republican primary. Massie had held the seat since 2012, and was considered to be popular within the district; in 2024 he had won the Republican primary with 76% of the vote, and the general election with 99.6% of the vote. President Donald Trump endorsed Gallrein on October 17, 2025. The primary was the most expensive congressional primary in U.S. history, costing over $25 million. Gallrein won the Republican nomination on May 19, 2026, 54.9%–45.1%, winning 19 of the 21 counties that voted. After the race against Massie was called in Gallrein's favor, Gallrein said: "It was a David versus Goliath. I was the underdog." Gallrein will face Democrat Melissa Strange in the general election on November 3, 2026.
== History == Life Length was established on September 28, 2010 by Stephen J. Matlin and Dr. María Blasco Marhuenda, as a spin-off from the Spanish National Cancer Research Centre. The founders had the objective to commercialize Blasco's HT Q-FISH conceptual work. In 2016, the company obtained CLIA certification, a U.S. government accreditation for clinical laboratories, becoming the only laboratory in Spain with this certification. In 2017, the ONCOCHECK project, which involves a series of clinical studies focused on cancer diagnostics, received €3.1 million in funding from the European Union's Horizon 2020 research and innovation program. In 2021, Life Length opened a clinic at Paseo del General Martinez Campos, 46, in Madrid. In 2022, the company's prostate cancer diagnostic tool received approval from the Spanish Agency for Medicines and Health Products (AEMPS). The same year, the company launched HEALTHTAV, a new product in its portfolio.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.